pre-IPO PHARMA

COMPANY OVERVIEW

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. Asher Bio was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and is located in South San Francisco.


LOCATION

  • South San Francisco, CA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://asherbio.com/


    CAREER WEBSITE

    https://asherbio.com/careers/


    SOCIAL MEDIA


    INVESTORS

    alexandra-venture-investments boxer-capital invus janus-henderson-investors logos-capital mission-biocapital third-rock y-combinator


    PRESS RELEASES


    Jun 22, 2023

    Asher Bio Presents New Preclinical Data Further Supporting Development of AB359 for Chronic Hepatitis B Virus at EASL International Liver Conference 2023


    Mar 14, 2023

    Asher Bio to Highlight Pipeline Programs in Presentations at AACR Annual Meeting 2023


    Jan 17, 2023

    Asher Bio Announces Dosing of First Patient in Phase 1a/1b Clinical Trial of AB248, a Cis-targeted IL-2 Immunotherapy Product Candidate, for the Treatment of Locally Advanced or Metastatic Solid Tumors


    Jan 5, 2023

    Asher Bio Appoints Independent Director Elaine Sun to Its Board


    Dec 12, 2022

    Asher Bio Presents New Preclinical Data at ASH Applying Cis-Targeted Cytokines to Enhance CAR-T Cell Therapies


    For More Press Releases


    Google Analytics Alternative